NOTE 1 – Organization and Recent
Developments Organization Sonoma Pharmaceuticals, Inc. (the “Company”)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company’s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020. The Company
is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range
of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company’s products
reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies
of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company’s stabilized
HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells
in the area treated assisting the body in its natural healing process. The Company sell its products either directly or via partners in
54 countries worldwide.
Free historical financial statements for Sonoma Pharmaceuticals Inc.
See how revenue, income, cash flow, and balance sheet financials have changed over 51 quarters since 2011. Compare with SNOA stock chart to see long term trends.